Such alterations have been previously reported as acquired mechanisms of resistance to anti-EGFR therapies in CRC.20,33 Collectively these and our data point to a diverse, heterogeneous landscape of potential resistance mechanisms adapted by RAS wild-type CRC tumors to overcome EGFR blockade. Here, EGFR is linked to colorectal carcinoma.